Early diagnosis of AL amyloidosis in haematology, cardiology, neurology, renal and general clinics: A British Society for Haematology Guideline

British Journal of Haematology 2026 Open access

Read full text
Authors: Mamta Garg, Satarupa Choudhuri, Christopher Parrish, Stephen Hawkins, Helen Jane Lachmann, Louise Clayton, Judith Richardson, Y. L. Tracey Chan, Ashutosh Wechalekar
DOI: 10.1111/bjh.70472
Cited by: 1
References: 17

Abstract

AL amyloidosis is caused by a plasma cell clone that produces abnormal light chains that misfold and deposit as amyloid fibrils in tissues and thus affect organ function. The survival of patients with systemic amyloid light-chain (AL) amyloidosis largely depends on the extent of end-organ damage. Patients with early-stage disease can expect approximately 80% survival at 5 years with contemporary treatment, compared to less than 30% for those with advanced disease. The aim of this guideline is to facilitate recognition and raise suspicion of amyloidosis. It is important to recognise that amyloidosis can present in any clinic, including general medicine/care of the elderly and general practice.

Fields of Study & Subjects

Amyloidosis: Diagnosis Treatment Outcomes Alzheimer's disease research and treatments Multiple Myeloma Research and Treatments

Publication details

Journal / source
British Journal of Haematology
Publisher
Wiley
Volume
208
Issue
6
Pages
1931–1938
Publication date
7 May 2026
Language
EN